SHIYAN, China--(BUSINESS WIRE)--On November 19, the 2026 Overseas Commercial Vehicle Partnership Summit was held in Shiyan, Hubei Province. During the Summit, Dongfeng G Series high-end truck brand has offically launched for overseas markets. Integrating top-tier global supply chains and having undergone rigorous testing, the G Series offers outstanding durability and cost efficiency. With leading technologies benchmarking against world-class brands, it aims to provide efficient transportation solutions for ...

Key Information - Rathbones Group Plc disclosed a position in Bluefield Solar Income Fund Ltd, holding 8,572,993 shares, representing 1.44% of the relevant securities [1][3] - The position was disclosed as of December 15, 2025, with the disclosure made on December 16, 2025 [1][14] Positions of the Discloser - The disclosed interests include 8,572,993 ordinary shares of 0.01p, which accounts for 1.44% of the total relevant securities [3] Dealings - Rathbones Group Plc sold 7,200 shares of 0.01p ordinary shares at a price of 67.509p per unit [7]

With a market cap of $9.1 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing markets. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. Companies valued less than $10 billion are generally classified as “mid-cap” stocks, and Bio-Techne fits this criterion perfectly. The company’s offerings support applications ranging ...

Core Insights - Arch Biopartners Inc. has received ethics approval from the University Health Network Research Ethics Board for St. Michael's Hospital to participate in the Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2] Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD), with a pipeline targeting inflammation- and toxin-related kidney injury [17] Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients, where subjects will receive either LSALT peptide (10mg IV twice daily for five days) or placebo [5] - The primary objective is to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery, as defined by KDIGO criteria [5][6] Current Status of the Trial - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network, with operational approvals and training underway before patient enrollment [2][4] - Other sites, including Toronto General Hospital and the University of Calgary, are actively enrolling patients, while Royal Columbian Hospital has received REB approval and is preparing for site initiation [4] Medical Context - CS-AKI is a common complication following cardiac surgery, affecting up to 30% of patients undergoing on-pump procedures, leading to serious complications and increased mortality [11][12] - There are currently no approved therapies for CS-AKI, highlighting a significant unmet medical need that LSALT peptide aims to address [12] Mechanism of Action - LSALT peptide is designed to prevent inflammation injury in the kidneys, lungs, and liver by binding to the dipeptidase-1 (DPEP1) enzyme, which plays a role in triggering organ inflammation [8] - Pre-clinical models have demonstrated LSALT's ability to prevent ischemia-reperfusion injury to the kidneys, supporting its therapeutic potential [8] Previous Research Findings - An earlier Phase II trial for acute lung inflammation showed that patients treated with LSALT peptide had significant reductions in inflammatory biomarkers, validating DPEP1 as a therapeutic target [9]

Core Viewpoint - Arch Biopartners Inc. has received ethics approval for St. Michael's Hospital to participate in a Phase II trial evaluating LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2]. Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD) [16]. - The company is advancing an integrated program targeting inflammation- and toxin-related kidney injury, with LSALT peptide as its lead drug candidate [16]. Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients [5]. - Patients will be randomized to receive either LSALT peptide (10mg IV twice daily for five days) or placebo, with the primary objective being to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery [5][6]. Research and Development - The trial aims to address a significant unmet medical need, as up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI, which can lead to serious complications and increased mortality [11]. - LSALT peptide works by binding to the dipeptidase-1 (DPEP1) enzyme, inhibiting its role in triggering organ inflammation, and has shown promise in pre-clinical models for preventing ischemia-reperfusion injury to the kidneys [8][7]. Collaboration and Site Activation - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network [2]. - Other active sites include Toronto General Hospital and the University of Calgary, with additional sites being evaluated in Canada and the United States [4].

Consortium Brand Partners is getting into the food business. The New York-based consumer brand investment platform that owns Draper James, Outdoor Voices and Jonathan Adler is part of a group that is acquiring California Pizza Kitchen. More from WWD The purchase price was not disclosed, but under the terms of the deal, Consortium is buying the business with Eldridge Industries, Aurify Brands and Convive Brands. Bain Capital Credit is supporting the deal with a debt and equity investment. It is expected ...

Group 1 - The market for critical minerals has shifted from a basic commodity model to one focused on national security and supply chain reliability [1] - There is a growing emphasis on identifying companies with strong brand recognition, solid financials, and growth potential within the consumer products sector [1] - Understanding consumer trends is crucial for identifying profitable investment opportunities in the industry [1]

YZi Labs has backed a string of BNB-based prediction market platforms. Credit: CCN. Key Takeaways Binance’s venture arm, Yzi Labs, has invested in several projects building prediction markets on BNB. The firm has a strong track record for incubating platforms that copy and expand on an established model. For instance, Pancake Swap and Aster frequently support greater trading volumes than the platforms they were inspired by. A year ago, prediction markets were dominated by Polymarket. But in 2025, ...

DexCom, Inc. ( DXCM ), a large-cap proxy on the medical equipment market, hasn’t quite managed to deliver the goods for its shareholder base in 2025 so far. Admittedly, the broad medical equipment industry has hardlyAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other tha ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported solid results for the quarter but did not keep pace with the sharp rally, thus lagging the benchmark. The market’s preference for lower-quality companies persisted in the quarter and contributed significantly to the benchmark’s outperformance. On the other hand, the strategy remains focused on higher-quality compa ...